Compare LINC & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINC | CSTL |
|---|---|---|
| Founded | 1946 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.0M | 661.7M |
| IPO Year | 2005 | 2019 |
| Metric | LINC | CSTL |
|---|---|---|
| Price | $22.65 | $39.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $26.67 | ★ $38.67 |
| AVG Volume (30 Days) | 262.8K | ★ 431.2K |
| Earning Date | 11-10-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.12 | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $494,742,000.00 | $343,530,000.00 |
| Revenue This Year | $17.79 | N/A |
| Revenue Next Year | $9.23 | N/A |
| P/E Ratio | $50.41 | ★ N/A |
| Revenue Growth | ★ 16.90 | 10.15 |
| 52 Week Low | $14.10 | $14.59 |
| 52 Week High | $25.76 | $40.61 |
| Indicator | LINC | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 62.20 | 78.85 |
| Support Level | $20.25 | $38.69 |
| Resistance Level | $20.89 | $40.61 |
| Average True Range (ATR) | 0.97 | 1.53 |
| MACD | 0.29 | -0.05 |
| Stochastic Oscillator | 96.53 | 86.08 |
Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include; Campus Operations, and Transitional. The majority of the revenue is generated from the Campus Operations segment which includes all campuses that are continuing in operation and contribute to the Company's core operations and performance.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.